Pacific Biosciences of California, Inc. (PACB) Q4 2025 Earnings Call Transcript

Pacific Biosciences of California, Inc. (PACB) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 14, 2026

PacBio Q4 Earnings and Revenues Beat Estimates, Gross Margin Up

PACB beats Q4 estimates as revenue jumps 14%, gross margin hits 41% and 2026 revenues are projected in the range of $165-$180M after strategic moves.

Zacks Investment Research • Feb 13, 2026

Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.2 per share a year ago.

Zacks Investment Research • Feb 12, 2026

PacBio Completes Sale of Short-Read Sequencing Assets

MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of select intellectual property and other assets related to PacBio's short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina, Inc.

GlobeNewsWire • Feb 2, 2026

Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market

In the most recent trading session, Pacific Biosciences of California (PACB) closed at $2.26, indicating a -4.64% shift from the previous trading day.

Zacks Investment Research • Jan 31, 2026

PacBio: The Consumables Flywheel Is Turning. The Chart Wants Confirmation

Pacific Biosciences is transitioning to a recurring revenue model as consumables reach a record 55% of Q3 revenue, driving margin improvements. Non-GAAP gross margin hit 42% in Q3, with management attributing gains to a favorable mix shift and yield improvements, notably from multi-use SMRT Cells. Cash burn is materially lower, with year-end cash at $279.5M and Q3 burn around $16M, supporting the company's path toward self-funding.

Seeking Alpha • Jan 28, 2026

PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, at 5:00 pm Eastern Time.

GlobeNewsWire • Jan 27, 2026

Pacific Biosciences of California (PACB) Stock Dips While Market Gains: Key Facts

Pacific Biosciences of California (PACB) closed the most recent trading day at $2.58, moving 3.37% from the previous trading session.

Zacks Investment Research • Jan 24, 2026

PacBio Stock Up on HiFi Sequencing Adoption for Major SUDC Research

PACB stock jumps as HiFi whole-genome sequencing becomes first-line in major SUDC research, highlighting adoption momentum.

Zacks Investment Research • Jan 15, 2026

Pacific Biosciences of California, Inc. (PACB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Pacific Biosciences of California, Inc. (PACB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 12, 2026